Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions.

ABSTRACT: Acute myeloid leukemia (AML) represents a heterogeneous group of high-grade myeloid neoplasms of the elderly with variable outcomes. Though remission-induction is an important first step in the management of AML, additional treatment strategies are essential to ensure long-term disease-free survival. Recent pivotal advances in understanding the genetics and molecular biology of AML have allowed for a risk-adapted approach in its management based on relapse-risk. Allogeneic hematopoietic cell transplantation (allo-HCT) represents an effective therapeutic strategy in AML providing the possibility of cure with potent graft-versus-leukemia reactions, with a demonstrable survival advantage in younger patients with intermediate- or poor-risk cytogenetics. Herein we review the published data rega

SUBMITTER: Kanate AS 

PROVIDER: S-EPMC3999783 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature